The Department of Biotechnology (DBT), under the Ministry of Science and Technology, launched Phase III of the Biomedical Research Career Programme (BRCP) on July 18, 2026, with a total outlay of ₹1,500 crore. The programme is designed to nurture globally competitive scientists and strengthen India’s biomedical research ecosystem over the coming years.
BRCP Phase III extends a fellowship and grant framework first introduced to reverse brain drain in the life sciences, offering structured career tracks for early-career researchers, principal investigators, and research institutions. The ₹1,500 crore allocation will fund fellowships, research infrastructure grants, and institutional capacity building across DBT-affiliated centres and partner universities.
How Will the ₹1,500 Crore Be Allocated Under BRCP Phase III?
The outlay is expected to be split across three broad heads: individual research fellowships for scientists at early and mid-career stages, infrastructure grants for laboratories working on genomics, cell biology and translational medicine, and institutional support for research training. DBT has indicated that a portion of funding will specifically target researchers returning from overseas postdoctoral positions.
What Do Scientists and Research Bodies Say About the Programme?
Biomedical research bodies have welcomed the continuity of BRCP into a third phase, noting that predictable multi-year funding is critical for retaining talent in India rather than losing scientists to better-funded labs abroad. Officials at DBT have framed the programme as central to India’s ambition of becoming a global hub for biotech innovation and vaccine and diagnostics research.
Market and Trade Reaction
While BRCP is a public research grant programme rather than a market-moving policy, listed biotech and life sciences companies with research collaborations with DBT-funded institutions are likely to benefit indirectly from an expanded talent pipeline. Industry body BioAsia has previously called for sustained government investment in research fellowships as a precondition for India’s biotech exports to scale.
What Happens Next?
DBT is expected to open applications for Phase III fellowships in the coming months, with eligibility criteria and selection timelines to be notified separately. Progress under the programme will likely be reviewed alongside India’s broader BioE3 (Biotechnology for Economy, Environment and Employment) policy framework.
Frequently Asked Questions
What is the Biomedical Research Career Programme?
BRCP is a DBT initiative that funds fellowships and research infrastructure for scientists working in biomedical and life sciences fields in India, aimed at building a globally competitive research workforce.
How much funding has been approved for Phase III?
Phase III of BRCP was launched on July 18, 2026, with a total outlay of ₹1,500 crore covering fellowships, infrastructure grants and institutional support.
Who can apply for BRCP fellowships?
The programme targets early and mid-career biomedical researchers, including scientists returning from overseas postdoctoral positions, though detailed eligibility norms are expected to be notified by DBT separately.
Leave a comment